Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALNEO: Neoadjuvant Alectinib in ALK+ NSCLC
NCT05015010Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Major Pathological Response at 12 weeks. Started May 2021; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05015010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015010.